Mental Health

Hans Eriksson, MD, PhD, the chief clinical development officer at HMNC Brain Health, on the development of personalized treatments for neuropsychiatric disorders using precision-medicine.

Shawn Singh, CEO of VistaGen, discusses how to improve and more effectively treat mental health disorders for returning veterans, who currently account for 20% of all suicides in the United States.

A panel of experts in the field of ketamine therapy discuss the role of the pharmacist in this field and the future of ketamine and assisted therapies based on current medical research.

September is National Recovery Month, so Pharmacy Times interviewed Rich Dion, PharmD, of Wolters Kluwer, Health, on the critical role of the hospital pharmacist in ongoing efforts to fight the opioid epidemic.

In a study, 92.5% of patients treated with the 6-month regimen of Invega and 95% of patients treated with the 3-month regimen were relapse-free at 12 months.

Peter Koshland, PharmD, CEO of Koshland Pharm and a practicing pharmacist, discusses whether the process may be similar in the future in terms of compounding pharmacies’ role in the administration of psychedelic drugs like psilocybin.

Peter Koshland, PharmD, CEO of Koshland Pharm and a practicing pharmacist, discusses how compounding pharmacies manage quality assurance when putting together ketamine dosages for patients.

Cities were ranked on a 50 point scale, weighing factors including therapy session rate by state, total prescription charges by state, their grade for mandatory treatment laws by state, criminalization of mental illness by state, number of residents per 1 mental health provider by county, poor mental health days by county, and overall community wellbeing.

Peter Koshland, PharmD, CEO of Koshland Pharm and a practicing pharmacist, discusses the role of the pharmacist in ketamine therapy.

Col. Dallas Hack, director of medical affairs at MagicMed, discusses the drug development program of a novel derivative of psilocybin for the treatment of post-traumatic stress disorder.

The amount of green space surrounding children’s homes may impact the development of ADHD.

Nicholas Mathews, co-founder of Stillwater Behavioral Health, discusses how pharmacists can respond to the identification of potentially problematic opioid prescription practices at sober-living facilities.

Although ADHD is generally treated through medication and/or behavioral treatments, in more than 25% of children, these treatments alone are insufficient.

Study suggests attention-deficit hyperactivity disorder medications may lower the risk of suicide in children with hyperactivity, oppositional defiance, and other behavioral disorders.

Antidepressants may lower the risk of death and serious complications from diabetes for patients with both diabetes and depression, according to a study published in the Journal of Clinical Endocrinology & Metabolism.

Clive Ward Able, MD, BPharm, discusses research results suggesting the promise of psilocybin as a potential treatment for obesity.

In addition to getting outside and taking time to enjoy hobbies outside of work, Carroll urged pharmacists to enjoy time with family and friends whenever possible.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy.

Individuals with attention-deficit hyperactivity disorder and other diagnoses who are taking stimulant medications are also more likely to switch to non-stimulant medications.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

Trials assessing psychedelic medicine were conducted in the United States for several decades before they were criminalized in 1968, with government and military funding provided for research in the field.

Pharmacy Times interviewed Dennis O’Neill, president and board member of BIOMEDICAN, on the outlook around the future of biosynthesis therapeutics that use rare cannabinoids to treat a range of health issues, from mental health disorders to diabetes.

Clive Ward Able, MD, BPharm, president of Clintell, consultant to NeonMind Inc, and a trained pharmacist and physician, discusses his research into the use of psychedelic compounds to treat obesity.

The messages offered alternatives to these prescription drugs and offered education for providers that is designed to lead to a change in medication.

Despite significant medical advancements related to HIV treatment and quality of life, the risk of suicide in patients is high and health care providers should prioritize mental health screenings in this population.

Bia Labate, PhD, public education and culture specialist at the Multidisciplinary Association for Psychedelic Studies, and Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discuss the psychedelic medicine market and the outlook for the field.

Jordan Tishler, MD, president of the Association of Cannabis Specialists and faculty at Harvard Medical School, discusses his outlook on the future of both care for patients with PTSD and acknowledgement of the role of cannabis in its treatment.

The omega-3 polyunsaturated fatty acids eicosapentaenoic acid and docosahexaenoic acid were applied first in high doses to lab-grown neurons and then in patients to understand the mechanism by which they reduce inflammation and depression.

The study authors said this research is the first systematic review that compares treatments for depression in those with coronary disease.